Knowledge Library

Isogeneic Trop-2 Model for Evaluating Anti-Trop-2 ADCs

Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where cytotoxic payloads released by antibodies diffuse and kill nearby tumor cells, is a crucial mechanism, particularly in heterogeneous tumors where not all cells express the target antigen. This effect can enhance ADC efficacy, especially when …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Antibody Drug Conjugate, Oncology, Tumor Models

VIEW

Development of Novel ADC-Resistant Models

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance. At the 2025 Festival …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Antibody Drug Conjugate, Oncology

VIEW

AACR 2025 Posters: Sneak Peek

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the largest and longest-standing cancer research conferences in the world, will be held in Chicago. At this year’s AACR meeting, WuXi Biology has been selected to present several posters detailing latest scientific insights, covering a range …Read More >

Resource Type: Article, Blog
Resource Topic: Antibody Drug Conjugate, Oligonucleotides, Oncology, Tumor Models

VIEW

Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a combination therapy regimen for DLBCL that combines chemotherapy drugs with rituximab). Polatuzumab vedotin is an antibody-drug conjugate (ADC) used to treat DLBCL, both in first-line treatment and for relapsed or refractory cases. At the 2025 …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Antibody Drug Conjugate, Tumor Models

VIEW

Developing Resistant Models to Diverse ADC Drugs

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance. At the 2025 World …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Antibody Drug Conjugate, Tumor Models

VIEW

Targeting FAK Improves the Tumor Uptake of ADCs

Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset of patients remains refractory to ADC treatment.  WuXi AppTec contributed to a research article which demonstrated that excessive cancer-associated fibroblasts (CAFs) can form a fibrotic barrier within a tumor microenvironment, impeding the tissue uptake of …Read More >

Resource Type: Latest Science, Publication
Resource Topic: Antibody Drug Conjugate, Oncology, Tumor Models

VIEW

Strategies to Accelerate the Development of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges for project teams.  In our latest webinar, experts discuss methodologies for evaluating ADC efficacy, resistance, and immunogenicity that address both antibody-specific and payload-specific mechanisms through various multi-dimensional assays. This webinar offers a comprehensive perspective on …Read More >

Resource Type: Webinar
Resource Topic: Antibody Drug Conjugate

VIEW

Custom Antibody and Protein Preparation Services

WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies, surrogate antibodies, diagnostic antibodies, therapeutic antibodies Antibody drug conjugate services, including site-specific conjugation Related antibody services, including peptide design and recombinant protein production

Resource Type: Brochure
Resource Topic: Antibodies, Antibody Drug Conjugate, Immunology, Oncology

VIEW

T-DXd Resistant Tumor Models with ABCG2

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  One mechanism of resistance involves efflux of the ADC payload by the transporter …Read More >

Resource Type: Presentation
Resource Topic: Antibody Drug Conjugate, Oncology, Tumor Models

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!